Search
Nivolumab
go.drugbank.com/drugs/DB09035ApprovedInvestigational[L12129] Nivolumab was granted FDA approval on 22 December 2014.[L12129] It is also available in combination with [relatlimab] under the brand name Opdualag.[L41265,L49996,L50001] … [L12129] This antibody was produced entirely in mice and grafted onto human kappa and IgG4 Fc region with the mutation _S228P_ for additional stability and reduced variability.
Belatacept
go.drugbank.com/drugs/DB06681ApprovedInvestigationalFDA approved on June 15, 2011. … Structurally, abatacept is a glycosylated fusion protein with a MALDI-MS molecular weight of 92,300 Da and it is a homodimer of two homologous polypeptide chains of 357 amino acids each.
Secukinumab
go.drugbank.com/drugs/DB09029ApprovedInvestigational[A249840] Following its first global approval in Japan in December 2014, secukinumab was approved by the European Commission on January 15, 2015, and by the FDA a few days after (January 21, 2015). … [L39600] By blocking the actions of IL-17A, secukinumab works to inhibit the pro-inflammatory pathways that drive immune-mediated inflammatory disorders.
Products: COSENTYX SOLUTION FOR INJECTION IN PREFILLED SYRINGE 150MG/ML, Fraizeron 150mg/ml solution for injection in pre-filled penPoliovirus type 2 antigen (formaldehyde inactivated)
go.drugbank.com/drugs/DB10796ApprovedInvestigationalPoliovirus type 2 antigen is a suspension of poliovirus Type 2 (MEF-1) used in the active immunization of infants (as young as 6 weeks of age), children, and adults for the prevention of poliomyelitis … The vaccine contains purified and inactivated poliovirus type 2 that were grown from a continuous line of monkey kidney cells.
Mixtures: Dt Polio Adsorbed - Sus Im, VeroPol Injektionslösung in einer FertigspritzeVoxilaprevir
go.drugbank.com/drugs/DB12026ApprovedInvestigationalVosevi is approved for the treatment of adult patients with chronic HCV infection with genotype 1, 2, 3, 4, 5, or 6 infection [FDA Label]. … Notably, Vosevi is approved for use in patients with genotypes 1-6 who have been previously treated with an NS5A inhibitor, or patients with genotypes 1a or 3 infection and have previously been treated
Categories: Antivirals for treatment of HCV infectionsAuranofin
go.drugbank.com/drugs/DB00995ApprovedInvestigationalAuranofin is a gold salt that is capable of eliciting pharmacologic actions that suppress inflammation and stimulate cell-mediated immunity. … It has subsequently been listed by the World Health Organization as a member of the antirheumatic agent category. Auranofin appears to induce heme oxygenase 1 (HO-1) mRNA.
Synonyms: 2,3,4,6-Tetra-O-acetyl-1-thio-beta-D-glucopyranosato-S (triethylphosphine)gold, (1-Thio-beta-D-glucopyranosato)(triethylphosphine)gold 2,3,4,6-tetraacetateGadopiclenol
go.drugbank.com/drugs/DB17084ApprovedInvestigationalGadopiclenol is a gadolinium-based contrast agent (GBCA) based on a pyclen macrocyclic structure. … [L43817] In 2006, the use of GBCAs was associated with the development of nephrogenic systemic fibrosis (NSF), a rare disorder characterized by the thickening and hardening of skin and subcutaneous tissues
Categories: Diagnostic Uses of ChemicalsGuanfacine
go.drugbank.com/drugs/DB01018ApprovedInvestigational[L11277] Guanfacine was first described in the literature in 1974.[A189841] Guanfacine was granted FDA approval on 27 October 1986.[L11274] … tablet for the treatment of ADHD.
Dulaglutide
go.drugbank.com/drugs/DB09045ApprovedInvestigationaltherapy to diet and exercise in the management of 2 diabetes (T2DM). … [A236070] Dulaglutide was initially approved by the FDA in 2014, and in February 2020 was approved for use in patients with T2DM and multiple cardiovascular risk factors for the prevention of cardiovascular
Categories: Drugs Used in DiabetesProducts: Trulicity 1.5mg solution for injection in pre-filled pen, Trulicity 0.75mg solution for injection in pre-filled penDegarelix
go.drugbank.com/drugs/DB06699ApprovedInvestigationalChemically, it is a synthetic linear decapeptide amide with seven unnatural amino acids, five of which are D-amino acids. FDA approved on December 24, 2008. … Degarelix is used for the treatment of advanced prostate cancer.